Chemoradiotherapy in squamous cell carcinoma of head and neck cancers [La radiochimiothérapie dans les carcinomes épidermo?des des voies aérodigestives supérieures]

摘要

Concomitant chemoradiation (alone or adjuvant) provides a significant survival benefit of about 8% in head and neck squamous cell carcinomas. Platin-based (Al-Sarraf's cisplatin regimen or fluoro-uracile-carboplatin) chemoradiation is the standard treatment in locally advanced head and neck squamous cell carcinomas for patients ≤ 70-years-old. Anti-EGFR and altered fractionated radiotherapy regimens also provide significant survival benefit but are not indicated in the postoperative setting. They can be suggested in cases of contraindication to chemotherapy. The place of anti-EGFR after intensive induction regimens like the TPF scheme and as first line treatment is still being investigated.